neurocoach.
My Care Plan
Explore optionsMedications

MEDICATIONS

WELTRUZA (monthly olanzapine injection)

FDA-approved monthly subcutaneous olanzapine for adults with schizophrenia—a delivery option, not a proven improvement over every oral treatment.

NeuroCoach · Evidence explorerSources checked 2026-10-11Editorial draft · clinical review pending

How it works

A healthcare professional gives extended-release olanzapine under the skin once monthly. The antipsychotic active ingredient is established; this formulation uses a long-acting delivery system.

What the evidence says, use by use

Evidence is specific to the condition, population and—for devices—the exact product. One label never covers everything.

Schizophrenia & Psychosis: Treating schizophrenia in adults

Established
Who was studied / who it’s for: Adults with schizophreniaRegulatory status: FDA approved October 9, 2026 for adult schizophrenia. No loading dose, oral olanzapine supplementation or routine post-injection monitoring is required under this product's approved instructions.What this label means: Strong research and/or authoritative clinical guidelines support this specific use.

The Phase 3 SOLARIS trial supported approval with improvements in symptom, severity and functioning measures. It did not establish that monthly olanzapine is superior to every oral medication or another long-acting injection. Suitability depends on prior response, physical health, side effects, preference and access.

Sources: Teva Pharmaceuticals (October 9, 2026) · NIMH

Who usually provides it

Psychiatrist or another authorized prescribing and administering clinician.

Cautions & things to know

  • Olanzapine can cause substantial weight gain, elevated blood sugar, lipid changes and sedation; monitoring remains important.
  • Another olanzapine injection has been associated with post-injection delirium/sedation syndrome (PDSS); whether PDSS can occur with WELTRUZA is unknown.
  • Like other antipsychotics, it carries a boxed warning about increased mortality in older adults with dementia-related psychosis. It is not approved for that use.
  • Approval is not the same as immediate pharmacy availability or insurance coverage. Never change or stop antipsychotics without a prescriber.

Questions for a clinician

Conversation prompts, not a treatment plan.

  • How does my current medication work for symptoms and side effects, and what is the actual goal of switching?
  • How would weight, glucose, lipids, movement problems and sedation be monitored?
  • What is the visit schedule, access and coverage, and what would happen if a monthly injection were missed?

Educational, not medical advice. NeuroCoach is an educational and care-navigation resource, not a medical provider. Information about medications, supplements, therapies, devices, clinical trials and community experiences is provided for education and exploration and is not a recommendation, diagnosis or treatment plan. Evidence varies substantially among interventions. Decisions about medical or mental-health treatment should be made with an appropriately qualified healthcare professional. Do not start, stop or change medication, supplements or treatment based solely on information found here.

Sources

Sources checked 2026-10-11. Educational editorial draft; clinical review pending.

  1. WELTRUZA FDA approval and SOLARIS trial announcement Teva Pharmaceuticals (October 9, 2026)
  2. Schizophrenia NIMH